SCHEMBL6201463

SCHEMBL6201463

CCCCCC(=O)Nc1[c]cccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
LMNA P02545 2/20 0.51
CETP P11597 2/20 0.51
SOAT1 P35610 3/20 0.50
SOAT2 O75908 1/20 0.50
EP300 Q09472 1/20 0.49
EPHX2 P34913 1/20 0.48
ALDH1A1 P00352 1/20 0.47
POLB P06746 2/20 0.47
HDAC3 O15379 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
SPHK2 Q9NRA0 1/20 0.46
SPHK1 Q9NYA1 1/20 0.46
GAA P10253 1/20 0.46
NAMPT P43490 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3389145 0.98 CETP (0.54) NPC1RAB9ASMN1; SMN2LMNACETP
SCHEMBL2138775 0.98 CETP (0.54) NPC1RAB9ASMN1; SMN2LMNACETP
SCHEMBL10896302 0.98 CETP (0.54) NPC1RAB9ASMN1; SMN2LMNACETP
SCHEMBL3221873 0.98 CETP (0.54) NPC1RAB9ASMN1; SMN2LMNACETP
SCHEMBL1779857 0.98 CETP (0.54) NPC1RAB9ASMN1; SMN2LMNACETP
SCHEMBL55564 0.98 CETP (0.54) NPC1RAB9ASMN1; SMN2LMNACETP
SCHEMBL5694380 0.95 CETP (0.51) NPC1RAB9ASMN1; SMN2LMNACETP
SCHEMBL5122024 0.89 MAPK1 (0.51) NPC1RAB9ASMN1; SMN2LMNAALDH1A1
SCHEMBL2184127 0.83 HDAC1 (0.45) HDAC3HDAC1HDAC2MEN1KMT2A
SCHEMBL2182701 0.82 GAA (0.45) ALDH1A1POLBHDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3400231-A1 AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING MICROBIAL INFECTIONS Technion Research & Development Foundation Limited (IL) 2018-11-14 EP claimed
EP-3344641-A1 AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS Eloxx Pharmaceuticals Ltd. (IL) 2018-07-11 EP claimed
WO-2017118967-A1 AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING MICROBIAL INFECTIONS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2017-07-13 WO claimed
WO-2017037719-A1 AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS ELOXX PHARMACEUTICALS LTD. (IL) 2017-03-09 WO claimed
EP-3400232-A1 AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS Eloxx Pharmaceuticals Ltd. (IL) 2018-11-14 EP disclosed
EP-3400231-A1 AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING MICROBIAL INFECTIONS Technion Research & Development Foundation Limited (IL) 2018-11-14 EP disclosed
EP-3344641-A1 AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS Eloxx Pharmaceuticals Ltd. (IL) 2018-07-11 EP disclosed
WO-2017118967-A1 AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING MICROBIAL INFECTIONS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2017-07-13 WO disclosed
WO-2017118968-A1 AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS ELOXX PHARMACEUTICALS LTD. (IL) 2017-07-13 WO disclosed
WO-2017037719-A1 AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS ELOXX PHARMACEUTICALS LTD. (IL) 2017-03-09 WO disclosed
EP-1130017-B1 Azole derivatives and their use as superoxide radical inhibitors OTSUKA PHARMA CO LTD (JP) 2005-06-15 EP disclosed
EP-0934937-B1 Azole derivatives as superoxide radical inhibitor OTSUKA PHARMA CO LTD (JP) 2002-02-27 EP disclosed
US-RE37556-E1 (ALKOXYPHENYL)THIAZOLE DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2002-02-19 US disclosed
EP-1130017-A2 Azole derivatives and their use as superoxide radical inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2001-09-05 EP disclosed
US-6080764-A PROTECTING VARIOUS TISSUE CELLS FROM DISTURBANCES ASSOCIATED WITH ISCHEMIA AND BLOOD REPERFUSION IN HEART, BRAIN, KIDNEY, LUNG AND DIGESTIVE TRACT BY INHIBITING SUPEROXIDE-RELEASE BY NEUTROPHILIC LEUKOCYTES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2000-06-27 US disclosed
EP-0934937-A1 Azole derivatives as superoxide radical inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1999-08-11 EP disclosed
US-5677319-A THIAZOLE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-10-14 US disclosed
US-5643932-A PREVENTS CELL DAMAGE AFTER ISCHEMIA AND RE-PERFUSION, SUBSTITUTED THIAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-07-01 US disclosed
EP-0513387-A1 ACTIVE OXYGEN INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-11-19 EP disclosed
US-4717648-A BLACK AND WHITE DEVELOPING METHOD FUJI PHOTO FILM CO., LTD. (JP) 1988-01-05 US disclosed